George D. Yancopoulos
Net Worth

Last updated:

What is George D. Yancopoulos net worth?

The estimated net worth of Dr. George D. Yancopoulos is at least $806,660,295 as of 16 May 2024. He owns shares worth $452,005,085 as insider, has earned $258,295,210 from insider trading and has received compensation worth at least $96,360,000 in Regeneron Pharmaceuticals, Inc..

What is the salary of George D. Yancopoulos?

Dr. George D. Yancopoulos salary is $4,380,000 per year as Scientific Founder, Pres, Chief Scientific Officer & Director in Regeneron Pharmaceuticals, Inc..

How old is George D. Yancopoulos?

Dr. George D. Yancopoulos is 65 years old, born in 1960.

What stocks does George D. Yancopoulos currently own?

As insider, Dr. George D. Yancopoulos owns shares in one company:

Company Title Shares Price per share Total value
Regeneron Pharmaceuticals, Inc. (REGN) Scientific Founder, Pres, Chief Scientific Officer & Director 786,383 $574.79 $452,005,085

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN logo
REGN
Regeneron Pharmaceuticals, Inc.
$574.79

George D. Yancopoulos insider trading

Regeneron Pharmaceuticals, Inc.

Dr. George D. Yancopoulos has made 75 insider trades between 2003-2024, according to the Form 4 filled with the SEC. Most recently he sold 3,213 units of REGN stock worth $3,111,598 on 16 May 2024.

The largest trade he's ever made was exercising 442,267 units of REGN stock on 22 Dec 2021. As of 16 May 2024 he still owns at least 786,383 units of REGN stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 3,213 $968.44 $3,111,598
Sale
Common Stock 907 $967.4 $877,432
Sale
Common Stock 790 $972.22 $768,054
Sale
Common Stock 9,242 $975.48 $9,015,386
Sale
Common Stock 4,886 $976.52 $4,771,277
Sale
Common Stock 1,227 $977.38 $1,199,245
Sale
Common Stock 379 $978.18 $370,730
Sale
Common Stock 4,922 $971.56 $4,782,018
Sale
Common Stock 4,669 $970.26 $4,530,144
Sale
Common Stock 2,653 $973.8 $2,583,491
Sale
Common Stock 7,611 $974.51 $7,416,996
Sale
Common Stock 9,501 $969.39 $9,210,174
Sale
Common Stock 846 $970.36 $820,925
Sale
Common Stock 111 $965.69 $107,192
Sale
Common Stock 782 $966.29 $755,639
Sale
Common Stock 1,428 $967.45 $1,381,519
Sale
Common Stock 3,387 $968.43 $3,280,072
Sale
Common Stock 1,930 $969.14 $1,870,440
Sale
Common Stock 406 $971.28 $394,340
Sale
Common Stock 784 $972.5 $762,440
Sale
Common Stock 1,865 $973.43 $1,815,447
Sale
Common Stock 4,778 $974.47 $4,656,018
Sale
Common Stock 5,225 $975.6 $5,097,510
Sale
Common Stock 6,885 $976.56 $6,723,616
Sale
Common Stock 9,851 $977.42 $9,628,564
Sale
Common Stock 4,865 $978.44 $4,760,111
Sale
Common Stock 504 $979.87 $493,854
Sale
Common Stock 1,223 $980.72 $1,199,421
Sale
Common Stock 2,283 $981.52 $2,240,810
Sale
Common Stock 303 $982.29 $297,634
Sale
Common Stock 727 $983.88 $715,281
Sale
Common Stock 53 $984.02 $52,153
Sale
Common Stock 647 $985.62 $637,696
Sale
Common Stock 442 $986.4 $435,989
Sale
Common Stock 182 $987.38 $179,703
Sale
Common Stock 373 $988.36 $368,658
Sale
Common Stock 120 $989.14 $118,697
Option
Common Stock 25,155 N/A N/A
Option
2019 Performance Stock Units 25,155 N/A N/A
Sale
Common Stock 642 $803.3 $515,719
Sale
Common Stock 254 $804.38 $204,313
Sale
Common Stock 47 $805.55 $37,861
Sale
Common Stock 122 $801.16 $97,742
Sale
Common Stock 400 $810.3 $324,120
Sale
Common Stock 254 $800.59 $203,350
Sale
Common Stock 700 $806.47 $564,529
Sale
Common Stock 1,237 $802.54 $992,742
Sale
Common Stock 13,189 $800.08 $10,552,255
Option
Common Stock 442,267 $224.78 $99,412,776
Option
Non-Qualified Stock Option (right to buy) 203,204 $270.43 $54,952,458
Sale
Common Stock 49,227 $625.68 $30,800,103
Sale
Common Stock 773 $625 $483,125
Sale
Common Stock 50,000 $600.06 $30,003,000
Sale
Common Stock 80,000 $538.04 $43,043,040
Sale
Common Stock 80,000 $538.04 $43,043,040
Sale
Common Stock 80,000 N/A N/A
Option
Common Stock 398,079 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 398,079 $52.03 $20,712,050
Option
Non-Qualified Stock Option (right to buy) 398,079 N/A N/A
Option
Common Stock 398,079 $52.03 $20,712,050
Sale
Common Stock 21,835 N/A N/A
Sale
Common Stock 117,815 N/A N/A
Sale
Common Stock 102,777 N/A N/A
Option
Common Stock 246,736 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 246,736 N/A N/A
Sale
Common Stock 118,123 N/A N/A
Option
Common Stock 245,295 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 245,295 N/A N/A
Option
Common Stock 244,048 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 244,048 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 195,438 N/A N/A
Option
Common Stock 195,438 N/A N/A
Option
Common Stock 195,079 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 195,079 N/A N/A
Option
Common Stock 1,921 N/A N/A
Option
Incentive Stock Option (right to buy) 1,921 N/A N/A
Sale
Common Stock 43,348 N/A N/A
Sale
Common Stock 43,348 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 182,818 N/A N/A
Option
Common Stock 182,818 N/A N/A
Option
Incentive Stock Option (right to buy) 3,264 N/A N/A
Option
Common Stock 3,264 N/A N/A
Option
Common Stock 5,720 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 5,720 N/A N/A
Sale
Common Stock 88,987 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 189,463 N/A N/A
Option
Common Stock 189,463 N/A N/A
Option
Common Stock 4,705 N/A N/A
Option
Incentive Stock Option (right to buy) 4,705 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 9,599 N/A N/A
Option
Common Stock 9,599 N/A N/A
Sale
Common Stock 100,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 192,308 N/A N/A
Option
Common Stock 192,308 N/A N/A
Option
Common Stock 50,846 N/A N/A
Option
Incentive Stock Option (right to buy) 10,537 N/A N/A
Option
Common Stock 10,369 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 10,369 N/A N/A
Sale
Common Stock 33,165 N/A N/A
Sale
Common Stock 33,150 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 133,332 N/A N/A
Option
Common Stock 133,332 N/A N/A
Sale
Common Stock 27,713 N/A N/A
Sale
Common Stock 27,713 N/A N/A
Option
Incentive Stock Option (right to buy) 3,570 N/A N/A
Option
Common Stock 200,000 N/A N/A
Option
Common Stock 100,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 100,000 N/A N/A
Sale
Common Stock 26,991 N/A N/A
Option
Incentive Stock Option (right to buy) 26,991 N/A N/A
Option
Common Stock 100,000 N/A N/A
Sale
Common Stock 31,283 N/A N/A
Option
Common Stock 90,444 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 90,444 N/A N/A
Option
Incentive Stock Option (right to buy) 9,556 N/A N/A
Sale
Common Stock 3,100 N/A N/A
Option
Common Stock 9,556 N/A N/A
Sale
Common Stock 3,882 N/A N/A
Option
Incentive Stock Option (right to buy) 19,723 N/A N/A
Option
Common Stock 29,800 N/A N/A
Sale
Common Stock 11,066 N/A N/A
Sale
Common Stock 900 N/A N/A
Option
Incentive Stock Option (right to buy) 5,500 N/A N/A
Option
Common Stock 25,000 N/A N/A
Sale
Common Stock 299 N/A N/A
Sale
Common Stock 1,339 N/A N/A
Sale
Common Stock 26,211 N/A N/A
Option
Incentive Stock Option (right to buy) 5,000 N/A N/A
Sale
Common Stock 49,900 N/A N/A
Option
Common Stock 126,310 N/A N/A
Sale
Common Stock 1,339 N/A N/A

Regeneron Pharmaceuticals key executives

Regeneron Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: